Grants in Belgium

Closed

Funds industrial demonstrations that replace fossil-heat-driven process steps with electrically driven technologies to cut energy use and emissions.

Funds research into fuel-flexible gas turbine combustion technology for burning ammonia cleanly and efficiently.

Closed

Funds a full-size next-generation soldier system demonstrator, with built-in cascade funding for smaller companies to test their own tech within it.

Funds curiosity-driven, TRL0 fundamental research on air traffic management ideas outside the other listed priorities.

Closed

Funds qualification and certification work that matures modular armoured-vehicle technology, including greener variants, toward deployment.

Closed

Funds implementation research that tests how schools, workplaces and other non-health settings can help prevent or manage chronic disease in low- and middle-income countries and underserved communities.

Closed

Funds up to three teams, EUR 5-7 million each, to push mid-maturity launcher propulsion breakthroughs like staged combustion, hybrid, aerospike or autophage engines toward flight readiness.

Closed

Awards five prizes of EUR 950,000 each to low-maturity, breakthrough innovations anywhere in the access-to-space supply chain, short of a complete launch solution.

Closed

Funds around two research projects, each worth EUR 1 to 2 million, to adapt EU-built generative AI to African challenges in farming, health, cities and education.

Closed

Funds one coordination project to build a shared hub connecting Europe's generative-AI developers, users and AI Factories.

Closed

Funds consortia that build or adapt generative AI models on large-scale multimodal health data and prove their value with at least two real biomedical use cases.

Funds generative-AI tools that detect and respond to cyberattacks, or that automate compliance with EU cybersecurity law.

Closed

Funds research teams building interactive generative-AI agents that integrate medical imaging and health data to improve cancer diagnosis and treatment.

Funds around twelve open-topic chip Innovation Action projects — pilot lines, test beds, demonstrators or market-replication pilots — anywhere across the Chips JU's technology and application roadmap.

Funds late-stage clinical trials of vaccines, monoclonal antibodies and antivirals against a named list of lower respiratory tract infection pathogens in sub-Saharan Africa.

Funds clinical trials advancing new or improved antimalarial drug combinations toward registration and access in sub-Saharan Africa.

Funds 4 regional research networks in sub-Saharan Africa to run multi-country clinical trials and rapid outbreak-response research.

Funds Phase IIa-and-later clinical trials of new or shorter TB drug and chemoprophylaxis regimens for adults and children in sub-Saharan Africa.

Funds clinical trials of TB vaccine candidates and licensed vaccines targeting adolescents, adults and vulnerable groups in sub-Saharan Africa.

Funds clinical trials or large-scale implementation research on climate-sensitive water- and vector-borne disease control in sub-Saharan Africa and Europe.

Funds late-stage clinical trials on treating co-infections and co-morbidities in people living with HIV, not HIV itself, across sub-Saharan Africa.

Funds host institutions in sub-Saharan Africa to run Master's fellowships and short courses in epidemiology, biostatistics and infectious-disease modelling, worth up to EUR 90,000 per fellow.

Funds around ten early-stage chip research projects, TRL 3-4, that develop and lab-test innovative technologies against the Chips JU's roadmap of key application areas.

Closed

Funds research projects worth EUR 3.4 million each that test practices increasing the autonomy of persons with disabilities.